Company intelligence / Profile preview

Apil

Ownership: Private
Development stage: Other

Overview

Apil is a biotechnology company focused on the development of novel therapeutic agents targeting the apoptotic pathway for the treatment of cancer. The company's research centers on modulating key proteins involved in programmed cell death to overcome resistance in various malignancies. By leveraging its expertise in molecular biology and medicinal chemistry, Apil aims to advance a pipeline of small molecule inhibitors and peptide-based therapies. The company is currently in the pre-clinical stage, conducting foundational studies to validate its lead candidates for both solid tumors and hematologic cancers.

Therapeutic areas: Oncology
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on Apil.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apil.

Explore the full profile